Tappet

← Back to Tappet
Philadelphia feed of tappet.org
Health Care · Nov 19, 2026

American Association for Cancer Research - Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cancer. Cancer Research Catalyst took a deep dive in the latest developments, the status of clinical research, and the next frontiers for the field. The post Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53 appeared first on American Association for Cancer Research (AACR) .

https://www.aacr.org/blog/2026/11/06/cracking-undruggable-cancer-proteins-precision-oncology-meets-p53/

Join the conversation on Tappet